Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-10-19
2008-08-19
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C530S328000
Reexamination Certificate
active
07414029
ABSTRACT:
Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula:in-line-formulae description="In-line Formulae" end="lead"?X-A-RnYmin-line-formulae description="In-line Formulae" end="tail"?wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4′)-biphenylalanine or D-(4,4′)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.
REFERENCES:
patent: 5605814 (1997-02-01), Abramovitz et al.
patent: 5759789 (1998-06-01), Abramovitz
patent: WO 00/01445 (2000-01-01), None
patent: WO 00/16760 (2000-03-01), None
patent: WO 01/42281 (2001-06-01), None
Ngo et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox.” The Protein Folding Problem and Tertiary structure Prediction. Ed. K. Merz and L. Le Grand. Birkhauser, Boston, Ma. 491-495.
Berendsen, Herman. “A Glimpse of the Holy Grail?” Science, vol. 282, pp. 642-643. Oct. 23, 1998.
Rudinger, J. (1976). Peptide Hormones (Ed. J.A. Parson). University Park Press. Baltimore pp. 1-7.
MedlinePlus, A service of the U.S. national Library of Medicine and the National Institutes of Health. “Chornic renal failure.” Feb. 20, 2008 [retrieved on Mar. 19, 2008] Retrieved from Internet: <http://www.nlm.nih.gov/medlineplus/ency/article/000471.htm>.
The Foundation for IgA Nephropathy. “Chronic Renal Insufficiency” Feb. 7, 2008 [retrieved on Mar. 19, 2008], Retreived from the internet: <http://www.igan.ca/id76.html>.
Bastien et al., “Cloning, functional expression , and characterization of the human prostaglandin E2 receptor EP2 subtype,”J. Biol. Chem., 269(16):11873-11877, 1994.
Bhattacharya et al., “Developmental changes in prostaglandin E2 receptor subtypes in porcine ductus arteriosus,”Circulation, 100(16):1751-1756, 1999.
Bouayad et al., “Characterization of PGE2 receptors in fetal and newborn lamb ductus arteriosus,”Am. J. Physiol. Heart Circ. Physiol., 280(5):H2342-H2349, 2001.
Breyer et al., “Differentiation localization of prostaglandin E receptor subtypes in human kidney,”Am. J. Physiol., 270:F912-918, 1996.
Breyer et al., “Regulation of renal function by prostaglandin E receptors,”Kidney Int., 54 (Suppl. 67):S88-S94, 1998.
File WPIDS on STN. An. No. 2004-053231. New peptide antagonists of prostaglandin E2 receptor subtype EP4, useful for manufacturing a medicament for treating end-stage renal disease, acute renal failure, renal insufficiency or patent ductus arteriosus. Absrtact fir WO2003099857, EP1506220, CN162551, JP2006506327. Abstract only. 2004.
Freidlander et al., “PGE2 binding sites and PG-stimulated cyclic AMP accumulation in rat isolated glomeruli and glomerular cultured cells,”Mol. Cell. Endocrinol., 30:201-214, 1983.
Jacoby et al., “The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis,”Cancer Res., 60(18):5040-5044, 2000.
Li et al., “Inhibition of prostaglandin synthesis in newborn pigs increases cerebral microvessel prostaglandin F2α and prostaglandin E2 receptors, their second messengers and vasoconstrictor response to adult levels,”J. Pharmacol. Exp. Ther., 278(1):370-377, 1996.
Lieberthal and Nigam, “Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable,”Am. J. Physiol. Renal. Physiol., 278(1):F1-F12, 2000.
Morath et al., “Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney,”J. Am. Soc. Nephrol., 10:1851-1860, 1999.
Mutoh et al., “Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis,”Cancer Res., 62(1):28-32, 2002.
Narumiya et al., “Prostanoid receptors: structures, properties, and functions,”Physiol. Rev., 79(4):1193-1226, 1999.
Nguyen et al., “The prostaglandin receptor EP4 triggers remodeling of the cardiovascular system at birth,”Nature, 390:78-81, 1997.
Schlondorff et al., “Prostaglandins and other arachidonic acid metabolites in the kidney,”Kidney Int., 29:108-119, 1987.
Shattuck-Brandt et al., “Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms,”Mol. Carcinog., 24(3):177-187, 1999.
Singer and Epstein, “Potential of dopamine A-1 angonists in the management of acute renal failure,”Am. J. Kidney Dis., 31(5):743-755, 1998.
Smith et al., “Effect of gestational age, corticosteroids, and birth on expression of prostanoid EP receptor genes in lamb and baboon ductus arteriosus,”J. Cardiovasc. Pharmacol., 37(6):697-704, 2001.
Sugimoto et al., “Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney,”Am. J. Physiol., 266(5 Pt 2):F823-F828, 1994.
Tai et al., “Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interkeukin-6-induced osteoclast formation,”Endocrinology, 138(6):2372-2379, 1997.
Tornich et al., “Aqueous Solubilization of Transmembrane Peptide Sequences with Retention of Membrane Insertion and Function,”Biophysical J., 74:258-267, 1998.
Wright et al., “Prostanoid receptors: ontogeny and implications in vascular physiology,”Am. J. Physiol. Regul. Integr. Comp. Physiol., 281(5):R1343-1360, 2001.
Abran Daniel
Bergeron Annie
Moffett Serge
Peri Krishna G.
Fulbright & Jaworski LLP
Gupta Anish
Theratechnologies Inc.
LandOfFree
Antagonistic peptides of prostaglandin E2 receptor subtype EP4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonistic peptides of prostaglandin E2 receptor subtype EP4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonistic peptides of prostaglandin E2 receptor subtype EP4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006401